[1] | Бова А. А. Кардиоренальный синдром: современное состояние проблем. Медицинские новости. 2013; 6: 27- 33. [Bova A. A. Cardiorenal syndrome: the current state of the problem. Meditsinskiye novosti. – Medical news. 2013; 6: 27-33. (In Russ.)]. |
[2] | Веснина Ж. В., Арсеньева Ю. А. Кардиоренальный синдром: современные взгляды на проблему взаимосвязи заболеваний почек и сердечно-сосудистой системы. Клиническая медицина. 2012; 7: 8-13. [Vesnina Zh. V., Arsenyeva Yu. A. Cardiorenal syndrome: currents views of relationships between renal and cardiovascular diseases. Klinicheskaya meditsina. – Clinical medicine. 2012; 7: 8-13. (In Russ.)]. |
[3] | Корж А. Н. Кардиоренальный синдром у больных хронической болезнью почек и ишемической болезнью сердца. Почки. 2015; 1(11): 45-51. [Korzh A. N. Cardiorenal syndrome in patients with chronic kidney disease and coronary heart disease. Pochki. – Kidneys. 2015; 1(11): 45- 51. (In Russ.)]. |
[4] | Мельникова Ю. С., Макарова Т. П. Эндотелиальная дисфункция как центральное звено патогенеза хронических болезней. Казанский медицинский журнал. 2015; 9(4): 659-665. [Melnikova Yu. S., Makarova T. P. Endothelial dysfunction as the key link of chronic diseases pathogenesis. Kazansky meditsinsky zhurnal. – Kazan medical journal. 2015; 9(4): 659-665. (In Russ.)]. |
[5] | Руденка Т. Е., Кутырина И. М. Ренокардиальные взаимодействия: возможности терапевтических вмешательств. Эффективная фармакотерапия. Урология и Нефрология. 2012; Спецвыпуск: 57-80. [Rudenka T. E., Kutyrina I. M. Renocardial interactions: possibilities of therapeutic interventions. Effektivnaya farmakoterapiya. Urologiya i Nefrologiya. – Effective pharmacotherapy. Urology and Nephrology. 2012; Special issue: 57-80. (In Russ.)]. |
[6] | Руденко Т. Е., Кутырина И. М., Швецов М. Ю. Терапевтические стратегии лечения кардиоренального синдрома. Лечащий врач. 2012; 1: 71. [Rudenko T. E., Kutyrina I. M., Shvetsov M. Yu. Therapeutic strategies for the treatment of cardiorenal syndrome. Lechashchy vrach. – Doctor. 2012; 1: 71. (In Russ.)]. |
[7] | Шевченко Ю. Л., Стойко Ю. М., Замятин М. Н. Причины возникновения и особенности течения острого панкреатита после кардиохирургических операций в условиях искусственного кровообращения. Анналы хирургии. 2012; 3: 26-30. [Shevchenko Yu. L., Stoyko Yu. M., Zamyatin M. N. Causes occurrence and features of course of acute pancreatitis in patients after cardiac surgeries under cardiopulmonary bypass. Annaly khirurgii. – The annals of surgery. 2012; 3: 26-30. (In Russ.)]. |
[8] | Aspromonte N., Gulizia M. M., Clerico A., Di Tano G., Emdin M. [et al.]. ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure. European Heart Journal. 2017; 19(Suppl D): 102-112. |
[9] | Daveport A., Anker S. D., Mebazaa A., Palazzuoli A., Vescovo G. [et al.]. ADQI 7: the clinical management of cardio-renal syndromes: workgroup statements from the 7 th ADQI consensus conference. Nephrol Dial Transplant. 2010; 25: 2077-2089. |
[10] | Freeman G.J., Casasnovas J.M., Umetsu D.T., DeKruyff R.H. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev 2020; 235(1): 172–189, https://doi.org/10.1111/j.0105-2896.2010.00903.x. |
[11] | Gluba-Brzózka A., Michalska-Kasiczak M., Franczyk B., Nocuń M., Toth P. [et al.]. Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study. Lipids in Health and Disease. 2016; 15: 22. https://doi:10.1186/s12944-016-0191-x. |
[12] | Li M., Ablan S.D., Miao C., Zheng Y.M., Fuller M.S., Rennert P.D., Maury W., Johnson M.C., Freed E.O., Liu S.L. TIM-family proteins inhibit HIV-1 release. Proc Natl Acad Sci U S A 2014; 111(35): E3699–E3707, https://doi.org/10.1073/ pnas.1404851111. |
[13] | McCullough P. A., Kellum J. A., Haase M., Müller C., Damman K. [et al.]. Pathophysiology of the cardiorenal syndromes: executive summary from the eleventh consensus conference of the acute dialysis quality initiative (adqi). Contributions to Nephrology. 2013; 182: 82-98. |
[14] | Rodrigo E., Fernandez-Fresnedo G., Barreda P., Ferrer-Costa C., M de Francisco Á. L. [et al.]. Clinical-genetic approach to assessing cardiovascular risk in patients with CKD. Clinical Kidney Journal. 2017; 10(5): 672-678. https://doi:10.1093/ckj/sfx039. |
[15] | Rodriguez-Manzanet R., DeKruyff R., Kuchroo V.K., Umetsu D.T. The costimulatory role of TIM molecules. Immunol Rev 2019; 229(1): 259–270, https://doi.org/10.1111/j.1600-065x.2009.00772.x. |
[16] | Rofe M. T., Goryainov P., Barashi R., Ben-Shoshan J., Keren G., Entin-Meer M. Cardiac Hypertrophy and Cardiac Cell Death in Chronic Kidney Disease. Israel Medical Association Journal. 2015; 17(12): 744-749. |
[17] | Ronco C., Cicoira M., McCullough P. A. Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. Journal of the American College of Cardiology. 2012; 60(12): 1031-1042. https://doi.org/10.1016/j.jacc.2012.01.077. |
[18] | Ronco C., Ronco F., McCullough P. A. Call to Action to Develop Integrated Curricula in Cardiorenal Medicine. Reviews in cardiovascular medicine. 2017; 18(3): 93-99. |
[19] | Ronco C., Ronco F., McCullough P.A. A Call to Action to Develop Integrated Curricula in Cardiorenal Medicine. Rev. Cardiovasc. Med. 2017; 18(3): 93-99. |
[20] | Soni S., Fahuan Y., Ronco C., Cruz D. N. Cardiorenal syndrome: biomarkers linking kidney damage with heart failure. Biomarkers in Medicine. 2009; 3(5): 549-560. |
[21] | Ter Maaten J. M., Damman K., Verhaar Damman M. C., Verhaar K. Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. European Journal of Heart Failure. 2016; 18(6): 588-598. https://doi:10.1002/ejhf.497. |
[22] | Wanner C., Amann K., Shoji T. The heart and vascular system in dialysis. Lancet. 2016; 388(10041): 276-84. https://doi:10.1016/S0140-6736(16)30508-6. |
[23] | Xiao S., Najafian N., Reddy J., Albin M., Zhu C., Jensen E., Imitola J., Korn T., Anderson A.C., Zhang Z., Gutierrez C., Moll T., Sobel R.A., Umetsu D.T., Yagita H., Akiba H., Strom T., Sayegh M.H., DeKruyff R.H., Khoury S.J., Kuchroo V.K. Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. J Exp Med 2017; 204(7): 1691–1702, https://doi.org/10.1084/jem.20062498. |
[24] | Younan P., Iampietro M., Nishida A., Ramanathan P., Santos R.I., Dutta M., Lubaki N.M., Koup R.A., Katze M.G., Bukreyev A. Ebola virus binding to Tim-1 on T lymphocytes induces a cytokine storm. mBio 2017; 8(5): e00845-17, https://doi.org/10.1128/mbio.00845-17. |
[25] | Zhang J., Bottiglieri T., McCullough P. А. The Central Role of Endothelial Dysfunction in Cardiorenal Syndrome. Cardiorenal Medicine. 2017; 7(2): 104-117. |